Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies

JAMA

Volumn 305, Issue 2, 2011, Pages 183-190

  Rider, Lisa G ^a   Miller, Frederick W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHILD; CLINICAL FEATURE; DERMATOMYOSITIS; FEMALE; GENETIC RISK; HUMAN; IMMUNE RESPONSE; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE WEAKNESS; MYOSITIS; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STEM CELL TRANSPLANTATION;

EID: 78651399830     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1977     Document Type: Article

References (49)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
2. Oddis CV, Rider LG, Reed AM, et al; International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52(9):2607-2615.
3. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201-2212. (Pubitemid 351890413)
4. Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis. J Rheumatol. 1990;17(10):1329-1334.
5. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998. Arthritis Rheum. 2003;49(3):300-305.
6. Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008;35(3):445-447.
7. Miller FW. Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In: Koopman W, Moreland L, eds. Arthritis and Allied Conditions: A Textbook of Rheumatology. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1593-1620.
8. Needham M, Mastaglia FL. Inclusion body myositis. Lancet Neurol. 2007;6(7):620-631.
9. Wedderburn LR, Rider LG. Juvenile dermatomyositis. Best Pract Res Clin Rheumatol. 2009;23(5):665-678.
10. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy. Medicine (Baltimore). 1991;70(6):360-374.
11. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies. Medicine (Baltimore). 2006;85(2):111-127.
12. Okada S, Weatherhead E, Targoff IN, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003;48(8):2285-2293.
13. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis. Lancet. 2001;357(9250):96-100.
14. Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Clin Exp Dermatol. 2009;34(4):451-455.
15. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50(1):209-215.
16. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies. Rheumatology (Oxford). 2009;48(6):607-612.
17. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2009;60(7):2193-2200.
18. Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2008;26(5)(suppl 51):S109-S114.
19. Rider LG, Lachenbruch PA, Monroe JB, et al; IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425- 3435.
20. Trieu EP, Gross JK, Targoff IN. Immunoprecipitation-Western blot for proteins of low abundance. Methods Mol Biol. 2009;536:259-275.
21. Fischer A, Swigris JJ, du Bois RM, et al. Antisynthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719-1724.
22. O'Hanlon TP, Miller FW. Genetic risk and protective factors for the idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2009;11(4):287-294.
23. Chinoy H, Lamb JA, Ollier WE, Cooper RG. An update on the immunogenetics of idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009;21(6):588-593.
24. O'Hanlon TP, Rider LG, Schiffenbauer A, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum. 2008;58(10):3239- 3246.
25. Gourley M, Miller FW. Mechanisms of disease. Nat Clin Pract Rheumatol. 2007;3(3):172-180.
26. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):891-916. (Pubitemid 36008557)
27. Lyon MG, Bloch DA, Hollak B, Fries JF. Predisposing factors in polymyositis-dermatomyositis. J Rheumatol. 1989;16(9):1218-1224.
28. Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60(8):2499-2504.
29. Mahdi H, Fisher BA, Källberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009;41(12):1319-1324.
30. Sarkar K, Weinberg CR, Oddis CV, et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum. 2005;52(8):2433-2438.
31. Rider LG, Wu L, Mamyrova G, et al. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2010;49(12):2381-2390.
32. Dalakas MC.Mechanisms of disease. Nat Clin Pract Rheumatol. 2006;2(4):219-227.
33. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies. Expert Opin Pharmacother. 2009;10(7):1183-1190.
34. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28(6):659-682.
35. Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 1996;97(12):2905-2910.
36. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):779-798, vi.
37. Howard OM, Dong HF, Yang D, et al. HistidyltRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196(6):781-791.
38. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis. Arthritis Rheum. 2005;52(6):1824-1835.
39. Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(2):219-225.
40. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1496-1501.
41. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. Rheumatology (Oxford). 2004;43(4):491-496.
42. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase- associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439-2446.
43. Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. Clin Exp Rheumatol. 2009;27(6):1009-1016.
44. Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab. J Clin Rheumatol. 2009;15(7):338-340.
45. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies. Arthritis Care Res (Hoboken). 2010;62(9):1328-1334.
46. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877-880.
47. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670-1677.
48. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780-784.
49. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(pt 6):1536-1544.